By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostic technologies developer Health Discovery said today that it has licensed some of its biomarker-based testing tools for hematopoietic and solid tumor cancers to NeoGenomics for $1 million in cash, 1.4 million shares in NeoGenomics stock, milestone payments of up to $5 million, and ensuing royalties.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.